Background and objective Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease
with poor prognosis. Activated fibroblasts are the key effector cells in fibrosis, producing …

Background Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor
prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently …

Remodeling of the extracellular matrix (ECM) is both a cause and consequence of human
diseases ranging from organ fibrosis to cancer (1). Idiopathic pulmonary fibrosis (IPF) is a …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. The
IPF-conditioned matrix (IPF-CM) system enables the study of matrix–fibroblast interplay …

Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of extracellular
matrix, in particular, collagens. Two IPF therapeutics, nintedanib and pirfenidone, decelerate …

Background Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing disease with
challenging management. To find novel effective therapies, better preclinical models are …

Extract Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unknown
aetiology [1]. The prevalence of this devastating disease continues to increase, affecting …

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease characterized by fibroblast
proliferation, extracellular matrix deposition, destruction of pulmonary alveolar architecture …

Idiopathic pulmonary fibrosis (IPF) affects over 500,000 people in the United States and
Europe alone. The disease is characterized by progressive obliteration of normal alveolar …

Background Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Repetitive
injury and reprogramming of the lung epithelium are thought to be critical drivers of disease …